Cell Therapy
Cell therapies are living drugs that consist of human immune cells that are infused into the patient in order to eliminate cancer cells. These immune cells are normally equipped with a guidance system that enable the immune cells to recognize and thereby kill the cancer cells. These guidance systems are normally either chimeric antigen receptors (CARs) or T cell receptors (TCRs).
Cell therapies have cured cancer patients…
Cell therapies have delivered the longest-lasting responses in late-stage cancer patients, some considered “cured” and a number of approvals to date
…opening for accelerated approvals vs conventional biotech..
Due to compelling efficacy, approval can be fast with data from <100 patients catalyzing high value from early clinical phases
…however, largest wins still restricted to liquid cancers…
The majority of approvals, however, have been for treating liquid cancers; most unmet need is in solid cancer
…although, TCR-based therapies have shown promise in solid cancers…
The two approvals in solid cancers both use a T Cell Receptor (TCR) as the guidance system for the cell therapy to target solid cancer
…with TCR-NK uniquely positioned to scale the curative potential of cell therapies for solid cancers
Despite the successes with TCR based cell therapies, challenges remain:
- Solid cancers remain tough to treat and struggle to deliver long term responses
- Scaling global access to treatment
Zelluna has built a platform to take the curative potential of cell therapies to solid cancers at a global scale
TCR-NK Platform
Zelluna strongly believes in the power of cell therapies and aim to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale.
We aim to do this by combining the most powerful elements of the immune system namely the natural killer (NK) cell and the T cell receptor (TCR) into TCR-NK cell therapies. The NK cells are highly potent cancer killers, can be manufactured at large scale using healthy donor material and has a favorable safety profile. The TCR provides exquisite cancer cell targeting and enable the NK cells to find and eliminate cancer cells in the patient’s body.
Game changing platform
World leading cell therapy platform, leveraging the clinical successes, that may provide transformative treatments to solid cancer patients on a global scale
Capture the market of an entire therapeutic field
Strong IP position provides an unprecedented opportunity to capture the market of an entire therapeutic field
Near term clinical inflection point
Lead program on the verge of the clinic, pathway validated through pre-IND with FDA, providing a near term value inflection point and catalyzation of significant value creation from the novel platform
Accelerated approval
Approval path can be fast and with data from only <100 patients catalyzing high value from early clinical phases
“Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale”.
MultiClick Technology
The MultiClick technology is a novel click chemistry based conjugation technology that can potentially serve multiple drug modalities across various diseases.
The MultiClick platform consists of a flexible core molecule that can selectively couple several modules. Each module can consist of a defined multiple of e.g. a targeting unit (i.e. a molecule to guide the drug to a specific tissue or cell type) and an active entity (i.e. a molecule that exerts a desired effect within the tissue, such as cancer cell killing or immune cell activation).
The MultiClick platform also harbours a manufacturing profile deemed potentially favourable with respect to precision, yield, costs, and scalability compared to currently available options.